— Extended-releasebuprenorphine (BUP-XR) had lower rates of hospitalizations, emergency department (ED) visits, and outpatient physicianoïcevisitscompared to those receiving daily oral buprenorphine or no medications for opioid use disorder (MOUD)
— The study indicatesBUP-XR may be an important tool in reducing ED visits, improving healthcare resource utilization and patient outcomes
Indivior PLC (Nasdaq/LSE: INDV) today announced results from a new retrospective real-world study published in Drug and Alcohol Dependence Reports, which examined demographic and clinical factors associated with ED visits among adults diagnosed withopioid use disorder (OUD) over a six-month follow-up period.
https://mma.prnewswire.com/media/1814851/Indivior_Logo.jpg
Thestudy foundthatpatients treatedwithBUP-XR, intheformoftheonce-monthlylong-acting injectableformulationofbuprenorphine, had 57% lower odds of all-cause ED visits compared to those who received noMOUD. Additionally, patients treated with BUP-XR experienced significantly fewer hospitalizations and lower inpatient costs compared to those receiving daily oral buprenorphine or no MOUD.
“Opioidoverdose-relatedEDvisitsareacritical concernintheongoingopioid epidemic,” said ChristianHeidbreder,Ph.D., Chief ScientificOïcer at Indivior. “These findings underscore the clinical and economic value of long-acting injectable treatments ofOUD. By reducing ED and physician oïce visits, BUP-XR may help ease the burden on our healthcare system while supporting long-term recovery outcomes for patients.”
The Indivior-funded study also revealed that patients treated with BUP-XR incurred lower inpatient healthcare costs. Inpatient costs for this group were nearly fivetimeslowercompared to patients receiving daily oral buprenorphine, and more than 10 times lower compared to patients receiving no MOUD. The BUP-XR cohort did have similar overall all-cause costs compared to the no MOUD cohort and had significantly higher overall costs compared to the daily oral buprenorphine cohort; this was primarily driven by higher outpatient pharmacy costs in the BUP-XR cohort, although it was not possible to determine if the BUP-XR medication itself was driving the diïEUR erence.
Hospitalization rates for BUP-XR were similarly lower: only 3% of BUP-XR-treated patients experienced an inpatient stay during the six-month follow-up period, versus 5% of those on dailyoralbuprenorphine.Notably,noopioid overdose-related ED visits were recorded among patients in the BUP-XR cohort during the study period; in the daily oral buprenorphine cohort there was a 1.2% overdose rate and 1% in the no MOUD cohort.
These findings are based on observed claims data and reïeect healthcare utilization during the defined study period. Although the results oïEUR er valuable insights for public health oïcials, emergency care providers, and policymakers, the study sample may not fully represent all individuals with OUD, particularly those who are uninsured or outside traditional healthcare systems. Additionally, the six-month observation window may not capture long-term treatment engagement or relapse risk.
Thefullstudyisavailablehere: Factorsassociatedwithemergencyroomvisitsamong patientswith opioid use disorder: A study of buprenorphine-treated and untreated patients – ScienceDirect
Disclosure:
Thispress releasehasbeenissuedbyIndivior Inc. and the content has not been approved or authorized by the College on Problems of Drug Dependence.
AboutSUBLOCADE®
SUBLOCADE® (buprenorphine extended-release) injection, for subcutaneous use, CIII INDICATION AND HIGHLIGHTED SAFETY INFORMATION
INDICATION
SUBLOCADEisindicatedforthetreatment ofmoderatetosevereopioidusedisorder inpatients who have initiated treatment with a single dose of a transmucosal buprenorphine product or who are already being treated with buprenorphine.
SUBLOCADE should be used as part of a complete treatment plan that includes counseling andpsychosocialsupport.
HIGHLIGHTEDSAFETYINFORMATION
WARNING: RISK OF SERIOUS HARM OR DEATH WITH INTRAVENOUS ADMINISTRATION; SUBLOCADE RISK EVALUATION AND MITIGATION STRATEGY
— Serious harm or death could result if administered intravenously. SUBLOCADE forms a solid mass upon contact with body ïeuids and may cause occlusion, local tissue damage,andthrombo-embolicevents, includinglife-threateningpulmonary emboli,if administered intravenously.
— Because of the risk of serious harm or death that could result from intravenous self- administration, SUBLOCADE is only available through a restricted program call the SUBLOCADE REMS Program. Healthcare settings and pharmacies that order and dispense SUBLOCADE must be certified in this program and comply with the REMS requirements.
CONTRAINDICATIONS
Hypersensitivitytobuprenorphineoranyother ingredientsinSUBLOCADE.
WARNINGSANDPRECAUTIONS
Addiction, Abuse, and Misuse: SUBLOCADE contains buprenorphine, a Schedule III controlled substance that can be abused in a manner similar to other opioids. Monitor patients for conditionsindicativeofdiversionorprogressionofopioid dependence and addictive behaviors.
Respiratory Depression: Life threatening respiratory depression and death have occurred in association with buprenorphine. Warn patients of the potential danger of self-administration ofbenzodiazepines or other CNS depressants while under treatment with SUBLOCADE.
Risk of Serious Injection Site Reactions: Likelihood of may increase with inadvertent intramuscular or intradermal administration. Evaluate and treat as appropriate. The most common injection site reactions are pain, erythema and pruritus with some involving abscess, ulceration and necrosis.
NeonatalOpioid WithdrawalSyndrome:Neonatal opioid withdrawal syndrome (NOWS) is an expected and treatable outcome of prolonged use of opioids duringpregnancy.
AdrenalInsuïciency:Ifdiagnosed,treatwithphysiologicreplacementofcorticosteroids,and wean patient oïEUR of the opioid.
Risk of Opioid Withdrawal with Abrupt Discontinuation: If treatment with SUBLOCADE is discontinued, monitor patients for several months for withdrawal and treat appropriately.
RiskofHepatitis,Hepatic Events:Monitorliver functiontestsprior toandduringtreatment.
RiskofWithdrawalinPatientsDependentonFullAgonist Opioids:Verifythatpatientshave tolerated transmucosal buprenorphine before injecting SUBLOCADE.
TreatmentofEmergentAcutePain:Treatpainwithanon-opioid analgesic whenever possible. If opioid therapy is required, monitor patients closely because higher doses may be required for analgesiceïEUR ect.
ADVERSEREACTIONS
Adverse reactions commonly associated with SUBLOCADE (in ≥5% of subjects) were constipation, headache, nausea, injection site pruritus, vomiting, increased hepatic enzymes, fatigue, and injection site pain.
Formoreinformationabout SUBLOCADE,thefullPrescribinginformationincludingBOXED WARNING, and Medication Guide, visit www.sublocade.com.
AboutOpioid UseDisorder(OUD)
Opioid Use Disorder (OUD) is a chronic disease in which people develop a pattern of using opioids that can lead to negative consequences.OUD mayaïEUR ectthepartsofthebrainthatare necessary for life-sustaining functions.
AboutIndivior
Indivior is a global pharmaceutical company working to help change patients' lives by developingmedicinestotreatopioid use disorder (OUD). Our vision is that all patients around the world will have access to evidence-based treatment forOUD and we are dedicated to transforming OUD from a global human crisis to a recognized and treated chronic disease.
Buildingonitsglobal portfolioofOUDtreatments,Indivior hasapipelineofproduct candidates designed to expand on its heritage in this category. Headquartered in the United States in Richmond, VA, Indivior employs over 1,000 individuals globally and its portfolio of products is available in over 30 countries worldwide. Visit www.indivior.com to learn more. Connect with Indivior on LinkedIn by visiting www.linkedin.com/company/indivior.
https://c212.net/c/img/favicon.png?sn=PH35555&sd=2025-07-23
View original content to download multimedia:https://www.prnewswire.com/news-releases/indivior-real-world-evidence-study-finds-medications-for-opioid-use-disorder-particularly-extended-release-buprenorphine-reduced-odds-of-emergency-department-visits-for-patients-with-opioid-use-disorder-302511427.html
SOURCE Indivior PLC
https://rt.newswire.ca/rt.gif?NewsItemId=PH35555&Transmission_Id=202507230800PR_NEWS_USPR_____PH35555&DateId=20250723